TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04174651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Description: Participants randomized to receive the acute stress condition will undergo the TSST wherein the participant will be introduced to an upcoming task (i.e., job interview) and allowed to prepare (2 minutes). The participant will then be required to speak (job interview) for 4 minutes in front of 2 experimenters. After completion of the interview, participants will be asked to perform a mental arithmetic task for 4 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Description: Participants randomized to receive the acute stress condition will undergo the TSST wherein the participant will be introduced to an upcoming task (i.e., job interview) and allowed to prepare (2 minutes). The participant will then be required to speak (job interview) for 4 minutes in front of 2 experimenters. After completion of the interview, participants will be asked to perform a mental arithmetic task for 4 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Landscape Video
Description: Participants randomized to receive the control condition will be watching a landscape video for 10 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Landscape Video
Description: Participants randomized to receive the control condition will be watching a landscape video for 10 minutes.
Study: NCT03634371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Levothyroxine 150 mcg
Description: Administration of a 600 mcg levothyroxine dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug Eutirox 150 mcg
Description: Administration of a 600 mcg levothyroxine dose
Study: NCT01463111

Intervention type: DRUG
Group type: OTHER
Intervention: Lithium
Description: Open label treatment per standard of care for bipolar disorder for six weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Valproate
Description: Open label treatment per standard of care for bipolar disorder for six weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Lamotrigine
Description: Open label treatment per standard of care for bipolar disorder for six weeks.
Study: NCT02995226

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical and biological examination, Saliva (or blood) test Glycemia, thermal test, cognitive and bike tests, questionnaires
Description: Clinical and biological examination, Saliva (or blood) test, glycemia, thermal test, cognitive and bike tests, questionnaires

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires
Description: Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires
Description: Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires
Study: NCT02786316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIT program
Description: HIT program for the rehabilitation of persons with NSCLBP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional rehabilitation program
Description: a conventional rehabilitation program in persons with NSCLBP
Study: NCT00195676

Intervention type: DRUG
Group type: OTHER
Intervention: adalimumab
Description: 40 mg every other week or 40 mg every week by subcutaneous injection
Study: NCT00646529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol (Symbicort)
Study: NCT00818987

Intervention type: OTHER
Group type: OTHER
Intervention: Open reduction internal fixation; reduction and immobilization
Study: NCT00855907

Intervention type: OTHER
Intervention: clinical evaluation
Description: Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome.~Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography.
Study: NCT02827331

Intervention type: OTHER
Intervention: Administrative and medical data
Description: * Gender~* Birthdate~* Department of residence~* City of residence~* Vital status (month and date of death)~* Affiliation to Universal Health Coverage~* Number of chronic long-term illness, medical diagnostic or pathology (CIM 10 code), onset and end dates~* Drugs reimbursements (Date of care onset, drugs identification code, number of box delivered)~* Data collected from medicalisation program of information system and private and public home care structures~* Medical consultations, medical acts ( Common Classification of Medical Acts nomenclature)

Intervention type: OTHER
Intervention: Administrative and medical data
Description: * Gender~* Birthdate~* Department of residence~* City of residence~* Vital status (month and date of death)~* Affiliation to Universal Health Coverage~* Number of chronic long-term illness, medical diagnostic or pathology (CIM 10 code), onset and end dates~* Drugs reimbursements (Date of care onset, drugs identification code, number of box delivered)~* Data collected from medicalisation program of information system and private and public home care structures~* Medical consultations, medical acts ( Common Classification of Medical Acts nomenclature)

Intervention type: OTHER
Intervention: Administrative and medical data
Description: * Gender~* Birthdate~* Department of residence~* City of residence~* Vital status (month and date of death)~* Affiliation to Universal Health Coverage~* Number of chronic long-term illness, medical diagnostic or pathology (CIM 10 code), onset and end dates~* Drugs reimbursements (Date of care onset, drugs identification code, number of box delivered)~* Data collected from medicalisation program of information system and private and public home care structures~* Medical consultations, medical acts ( Common Classification of Medical Acts nomenclature)
Study: NCT00901576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503
Description: SPD503 (guanfacine hydrochloride) extended-release 4 mg orally administered tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concerta
Description: CONCERTA (methylphenidate HCl) extended-release 36 mg orally administered tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPD503 + Concerta
Description: SPD503 4 mg + CONCERTA 36 mg orally administered tablets (taken together).
Study: NCT03423186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOBI003
Description: Weekly i.v.infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOBI003
Description: Weekly i.v.infusion
Study: NCT01973595

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almonds, Then no almonds
Description: Whole, raw almonds with skin, or whole, raw almonds with skin that have been ground into a paste.
Study: NCT02956850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to RO7020531 will be administered as per schedule specified in the respective arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to RO7020531 will be administered as per schedule specified in the respective arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to RO7020531 will be administered as per schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7020531
Description: RO7020531 will be administered as per schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7020531
Description: RO7020531 will be administered as per schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7020531
Description: RO7020531 will be administered as per schedule specified in the respective arm.
Study: NCT00392808

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: conjugated polysaccharide menC vaccine
Description: Booster vaccine dose at 14 to 18 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: conjugated polysaccharide menC vaccine
Description: Booster vaccine dose at 14 to 18 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: conjugated polysaccharide menC vaccine
Description: Booster vaccine dose at 14 to 18 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: conjugated polysaccharide menC vaccine
Description: Booster vaccine dose at 14 to 18 months.
Study: NCT01798641

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MIETHKE proGAV® / MIETHKE proSA®
Description: The programmable shunt will be adjusted through the MIETHKE proGAV® / MIETHKE proSA® valve and crossed over at 6 weeks. The open shunt will be adjusted to be closed. The closed shunt will be adjusted to open.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIETHKE proGAV® / MIETHKE proSA®
Description: The programmable shunt will be adjusted through the MIETHKE proGAV® / MIETHKE proSA® valve and crossed over at 6 weeks. The open shunt will be adjusted to be closed. The closed shunt will be adjusted to open.
Study: NCT00938977

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Before and after effect of treatment with CPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilevel Support Ventilation (Non-Invasive Ventilation)
Description: before/after effect of Bilevel support ventilation
Study: NCT01406496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin
Description: Three different timings of insulin delivered by a pump
Study: NCT00440856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Presentation of excised intervertebral disc fragments
Study: NCT03950713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction Program - Taiwan (MBSR-T)
Description: The MBSR-T is focused on strategies to manage diabetes distress for new residents by three new techniques. Firstly, it involves practicing body and meditation exercises for openness to the awareness and acceptance of transferred life experiences, such as mindful attention exercise, which is assumed to allow the residents to behave in a less reactive and more reflective manner when confronted with transferred life stressors. Second, mindfulness meditation techniques were provided for difficult thoughts and feelings related to diabetes, such as paying full attention to the present moment of life and choosing to respond skillfully rather than reacting automatically to external events, thoughts or emotions as they arise. Third, a specific topic, for example on how to be mindful when life style is changed, or how to pay attention to the present moment within Chinese culture of peacefulness was discussed in each session.
Study: NCT04827797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balls
Description: Birth balls to exercise

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balls
Description: Birth balls to exercise
Study: NCT04349241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: favipiravir
Description: pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), a new type of RNA-dependent RNA polymerase (RdRp) inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care therapy
Description: oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10
Study: NCT00247832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-directed motivation
Description: Post-lobectomy patients are provided with a booklet that outlines expected physical activities (sitting up, walking arm exercises) to aim for each day after surgery. It also provides room for the patients to record what they have accomplished.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal motivational interviewing
Description: Post-lobectomy patients receive daily visits from a study coordinator aimed to motivate the patient to complete various physical activities each day after surgery. The study coordinator goes through the same booklet that is given to Group 2 and helps patients set goals and record their accomplishments.
Study: NCT00027586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (STI571)
Description: 400 mg twice a day orally
Study: NCT00951249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral of Partners
Description: Referral of up to five sexual partners by index participants for enrollment into the study

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening for STIs and counseling
Description: Identification of STIs and treatment or referral for treatment, if applicable

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer health care system navigators
Description: HIV/STI treatment and other medical and social services

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced counseling
Description: Counseling and referral for care offered to participants for issues such as substance use and mental health
Study: NCT04348175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Setmelanotide will be administered as a single SC dose of 2.0 mg on Day 1. A dose higher than 2.0 mg will not be used during the study. Dose may be lowered based on safety data.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Setmelanotide will be administered as a single SC dose of 2.0 mg on Day 1. A dose higher than 2.0 mg will not be used during the study. Dose may be lowered based on safety data.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Setmelanotide will be administered as a single SC dose of 2.0 mg on Day 1. A dose higher than 2.0 mg will not be used during the study. Dose may be lowered based on safety data.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Setmelanotide will be administered as a single SC dose of 2.0 mg on Day 1. A dose higher than 2.0 mg will not be used during the study. Dose may be lowered based on safety data.
Study: NCT01718249

Intervention type: OTHER
Group type: OTHER
Intervention: Implantable neurostimulation system
Study: NCT01416441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole tablets orally once daily.
Study: NCT00151034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT00885768

Intervention type: PROCEDURE
Intervention: angiography
Description: all patients undergoing coronary angiography with VISIPAQUE and if they had coronary stenosis then renal artery angiography will be done. the dose of contrast will be chosen according to renal function and clinical conditions which will be varied from 75 to 300 ml.
Study: NCT04750980

Intervention type: OTHER
Intervention: food allergy
Description: food allergy

Intervention type: OTHER
Intervention: respiratory allergy
Description: respiratory allergy

Intervention type: OTHER
Intervention: healthy controls
Description: healthy controls
Study: NCT01668641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02757794

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: computerized cognitive remediation program
Description: a computer program online re-educating the working memory is completed by the parents and the child. The child made a series of interactive exercises accompanied by parents or a practitioner. The exercises are adapted automatically and individually to the performance at each session.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard remediation
Description: A speech therapy and / or academic support is realized.
Study: NCT03340896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg / m² administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion of one hour followed by cisplatin 75 mg / m² administered on day 1 hour infusion followed by 5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin: 75 mg/m² for experimental arm and 100mg/m² for comparator arm administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin: 75 mg/m² for experimental arm and 100mg/m² for comparator arm administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: 5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy : 70Gy (2Gy/day) for 7 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Radiotherapy : 70Gy (2Gy/day) for 7 weeks.
Study: NCT01291693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Counseling
Description: At three time-points, participants receive counseling by health professionals trained in Motivational Interviewing based counseling. To assure that both interventions do not differ in their content, individual manuals generated by a software program are used. Counseling will be face-to-face during the hospital stay, and by phone one and three months later.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-generated feedback letters
Description: At three time points, participants receive feedback letters, tailored to the stages of change according to the TTM, and generated by a computer software program. The first letter is handed out during their hospital stay and includes normative feedback. One and three months later, participants receive ipsative feedback letters by mail.
Study: NCT01544413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sentinel lymph node biopsy
Description: During the operation, endoscopic marking was perfomed using Tc 99m HSA and indocyanine green around tumor. Then we identify the sentinel lymph node with laparoscopic probe. Laparoscopic sentinel lymph nodes were dissedted and evaluated them at the backtable in the operating room.
Study: NCT02333149

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Children \<40 kg will take one tablet, melatonin 3 mg, oral, 30 - 60 minutes prior to bedtime.~Children ≥40 kg will take two tablets, melatonin 3 mg, oral, 30-60 minutes prior to bedtime.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo frequency and volume are identical to the experimental arm
Study: NCT05640206

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: i-PRF
Description: Arthrocentesis performed with two-needle technique, and then injection of i-PRF intra-articularly

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthrocentesis
Description: Arthrocentesis performed with two-needle technique
Study: NCT00313768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel + carboplatin + bevacizumab
Description: paclitaxel 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin + paclitaxel + bevacizumab + PF-3512676
Description: carboplatin AUC 6 intravenously on Day 1 of each 21 day cycle x 6 cycles
Study: NCT02251132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV low 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV low 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV low 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV medium
Study: NCT00646529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide (Pulmicort)
Study: NCT00324324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin hydrochloride
Description: Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
Study: NCT00305773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally three times daily
Study: NCT02027285

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortified milk
Description: FortifiedUltra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose \<0.5%) produced by Granarolo s.p.a. supplemented with long chain unsaturated fatty acids DHA (Docosahexaenoic acid) +EPA (Eicosapentaenoic acid), vitamin D, B12, B6, B9, E,C, Zinc and Selenium versus placebo Ultra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose \<0.5%) of the same manufacturer.~The nutrients added are: DHA + EPA 1.4 mg/ml; vitamin D3 0.068 mcg/ml; B6 6.4 mcg/ml; B12 0.01 mcg/ml; B9 (folic acid) 0.80 mcg/ml; vitamin E 0.05 mg/ml; vitamin C 0.19 mg/ml; Zinc 0.04 mg/ml; Selenium 0.22 mcg/ml. The protein content of the milk is 0.04 g/ml.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: fortified milk
Description: FortifiedUltra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose \<0.5%) produced by Granarolo s.p.a. supplemented with long chain unsaturated fatty acids DHA (Docosahexaenoic acid) +EPA (Eicosapentaenoic acid), vitamin D, B12, B6, B9, E,C, Zinc and Selenium versus placebo Ultra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose \<0.5%) of the same manufacturer.~The nutrients added are: DHA + EPA 1.4 mg/ml; vitamin D3 0.068 mcg/ml; B6 6.4 mcg/ml; B12 0.01 mcg/ml; B9 (folic acid) 0.80 mcg/ml; vitamin E 0.05 mg/ml; vitamin C 0.19 mg/ml; Zinc 0.04 mg/ml; Selenium 0.22 mcg/ml. The protein content of the milk is 0.04 g/ml.
Study: NCT02309372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beating the Blues
Description: Computerized depression treatment intervention
Study: NCT04898088

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells Transplantation
Description: Mesenchymal Stem Cells Transplantation applied as three intravenous infusions with 30 days intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells Transplantation
Description: Mesenchymal Stem Cells Transplantation applied as three intravenous infusions with 30 days intervals